Difficulty: Medium
Average Score: 91%
Practice
The following is/are true about 4C Men B protein vaccine (Bexsero®):
Correct answer
D
Rationale
The correct answer is option D: "Is licensed for use from 2 months of age." This is the correct answer because the 4C Men B protein vaccine (Bexsero®) is indeed licensed for use in infants as young as 2 months of age, as per the recommendations from regulatory agencies and medical authorities.
Option A: "Bexsero® may protect up to 98% of circulating Men B strains in England and Wales" is incorrect. While Bexsero® is effective against many strains of Men B, the specific percentage can vary based on geographical location and circulating strains.
Option B: "Bexsero® may also protect against infection by other capsular groups of meningococcus" is incorrect. Bexsero® primarily targets Men B strains and does not provide broad protection against other capsular groups of meningococcus.
Option C: "Is currently recommended for all household contacts of an index case of invasive group B meningococcal disease" is incorrect. While close contacts of individuals with meningococcal disease may be recommended to receive prophylactic treatment, the specific recommendation for Bexsero® may vary depending on the situation and guidelines in place.
Educational Context: Understanding the specifics of the 4C Men B protein vaccine (Bexsero®) is crucial for healthcare providers, especially those preparing for exams like the NCLEX. Knowing the age indication for the vaccine, its efficacy, and its limitations can help healthcare professionals make informed decisions when it comes to preventing and managing meningococcal disease in clinical practice.
Option A: "Bexsero® may protect up to 98% of circulating Men B strains in England and Wales" is incorrect. While Bexsero® is effective against many strains of Men B, the specific percentage can vary based on geographical location and circulating strains.
Option B: "Bexsero® may also protect against infection by other capsular groups of meningococcus" is incorrect. Bexsero® primarily targets Men B strains and does not provide broad protection against other capsular groups of meningococcus.
Option C: "Is currently recommended for all household contacts of an index case of invasive group B meningococcal disease" is incorrect. While close contacts of individuals with meningococcal disease may be recommended to receive prophylactic treatment, the specific recommendation for Bexsero® may vary depending on the situation and guidelines in place.
Educational Context: Understanding the specifics of the 4C Men B protein vaccine (Bexsero®) is crucial for healthcare providers, especially those preparing for exams like the NCLEX. Knowing the age indication for the vaccine, its efficacy, and its limitations can help healthcare professionals make informed decisions when it comes to preventing and managing meningococcal disease in clinical practice.